A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome

Acta Paediatr. 2005 Jun;94(6):779-84. doi: 10.1111/j.1651-2227.2005.tb01984.x.

Abstract

Aim: To compare the effects of beractant and poractant in neonatal respiratory distress syndrome (RDS).

Methods: Infants with RDS were randomized to receive beractant or poractant. The primary outcome measure was fraction of inspired oxygen (FiO2) requirement in the first 48 h after surfactant therapy.

Results: 58 infants completed the study. The mean gestational ages for the poractant and beractant groups were 29.6+/-3.6 and 29.3+/-2.9 wk, with average birthweights of 1394+/-699 and 1408+/-534 g, respectively. In the first 48 h, infants who received poractant had a lower FiO2 requirement compared to those who received beractant (p=0.018). The prevalence of patent ductus arteriosus (PDA) was lower in the group of infants that received poractant (17%) compared to the group that received beractant (45%) (p=0.02).

Conclusions: Infants with RDS treated with poractant had a lower FiO2 requirement during the first 48 h compared to infants who received beractant. Infants who received poractant also had fewer PDAs than infants who received beractant. The difference in FiO2 was not associated with a difference in age of first extubation, total intubation time, or incidence of bronchopulmonary dysplasia between groups.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biological Products / therapeutic use*
  • Female
  • Humans
  • Infant, Newborn
  • Male
  • Phospholipids / therapeutic use*
  • Pulmonary Surfactants / therapeutic use*
  • Respiratory Distress Syndrome, Newborn / drug therapy*
  • Treatment Outcome

Substances

  • Biological Products
  • Phospholipids
  • Pulmonary Surfactants
  • poractant alfa
  • beractant